Peter Guzzetti, DO
Internal Medicine · Augusta, MENPI 1306885207
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 693 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 693 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AstraZeneca$861
- Amgen$846
- GSK$828
- Boehringer Ingelheim$804
- Merck$649
- plus $5K from 27 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$10,60898%
- Education$1822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 210 | $1,909 |
| AstraZeneca | 46 | $861 |
| Amgen | 41 | $846 |
| GSK | 52 | $828 |
| Boehringer Ingelheim | 37 | $804 |
| Merck | 39 | $649 |
| Novo Nordisk | 34 | $624 |
| AbbVie(2 entities) | 41 | $588 |
| Exact Sciences | 20 | $467 |
| Lundbeck LLC | 14 | $427 |
| Astellas Pharma US Inc | 12 | $350 |
| Johnson & Johnson | 40 | $349 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $289 |
| Lilly USA, LLC | 10 | $239 |
| Novartis | 13 | $239 |
| Abbott | 11 | $198 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $188 |
| Sanofi Pasteur Inc. | 11 | $184 |
| Sanofi-aventis U.S. LLC | 9 | $141 |
| Nestle Healthcare Nutrition Inc. | 7 | $93 |
| Madrigal Pharmaceuticals | 3 | $79 |
| Phathom Pharmaceuticals, Inc. | 2 | $70 |
| Corcept Therapeutics | 2 | $64 |
| Sumitomo Pharma America, Inc. | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Bayer | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Verona Pharma, Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$10,790 in reported general payments places this provider in the 95th percentile of 445 internal medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $114,833 |
| JardianceEmpagliflozin | 63 | $94,322 |
| OzempicSemaglutide | 74 | $88,416 |
| TrulicityDulaglutide | 34 | $56,123 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $22,991 |
| XareltoRivaroxaban | 12 | $19,055 |
| MyrbetriqMirabegron | 14 | $18,980 |
| MounjaroTirzepatide | 17 | $17,882 |
| OxycontinOxycodone Hcl | 15 | $12,400 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,895 |
| JanuviaSitagliptin Phosphate | 12 | $6,643 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,320 |
| Rosuvastatin Calcium | 266 | $4,349 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 119 | $4,041 |
| Omeprazole | 233 | $3,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,909 | $114,833105 claims |
| Boehringer IngelheimJardiance | $804 | $94,32263 claims |
| Novo NordiskOzempic | $624 | $88,41674 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $239 | $74,00551 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $828 | $39,58558 claims |
| Johnson & JohnsonXarelto | $349 | $19,05512 claims |
| Astellas Pharma US IncMyrbetriq | $350 | $18,98014 claims |
| MerckJanuvia | $649 | $6,64312 claims |
| AbbVieSynthroid | $588 | $2,37024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 445 internal medicine providers in Maine.
Other internal medicine in Augusta
- Gene ChengAugusta$22K
- Donald StricklandAugusta$6K
- Nananda ColPortland$124K
- Heidi DeblockPortland$27K
- Elizabeth DennisWestbrook$17K
- Hassan AbouleishHoulton$15K
- Linford StillsonWestbrook$11K
- Peter LeightonBridgton$10K
- Tony VargheseBaltimore$8K
- Edwin TanAuburn$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.